CYP2C9 Risk Sim

Baseline Warfarin Therapy & Therapeutic INR

Placeholder: patient stable on warfarin, INR tracked in range.

• 2.0–3.0: Therapeutic INR Range (most warfarin indications)
• 20–60 h: Warfarin Half-Life (highly variable by patient)
• ~90%: CYP2C9 Metabolism Share (primary clearance enzyme)
• Narrow: Therapeutic Index (small safety margin)

Warfarin pharmacology basics

Placeholder: warfarin blocks vitamin K clotting factor synthesis.

Why CYP2C9 matters

Placeholder: CYP2C9 clears the potent S-warfarin enantiomer.

Placeholder: small clearance changes swing INR disproportionately.

Routine INR monitoring

Placeholder: regular blood draws keep dosing on target.

Cannabis / CBD Introduced Into Therapy

Placeholder: patient begins using CBD or cannabis products.

• 18–32 h: CBD Plasma Half-Life (accumulates with repeated dosing)
• Competitive: CYP2C9 Inhibition Type (reversible enzyme binding)
• Oil, edible, vape: Common CBD Products (variable bioavailability)
• Low: Patient Disclosure Rate (often unreported to clinicians)

Cannabinoids reach the liver

Placeholder: absorbed CBD circulates to hepatic tissue.

CBD vs THC effects

Placeholder: CBD is the stronger CYP2C9 inhibitor of the two.

A hidden interaction

Placeholder: patients rarely flag supplements as drug interactions.

Placeholder: ask every warfarin patient about cannabis use.

CYP2C9 Enzyme Activity Is Inhibited

Placeholder: cannabinoids occupy the enzyme active site.

• Low µM: CBD Ki (CYP2C9) (potent inhibitor range)
• Dose-dependent: Active-Site Occupancy (rises with CBD exposure)
• Phenytoin, NSAIDs: Other CYP2C9 Substrates (also affected)
• Days: Enzyme Recovery Time (after cannabinoid clears)

Competitive active-site binding

Placeholder: CBD physically blocks warfarin from docking.

Dose-response relationship

Placeholder: higher, more frequent CBD dosing deepens inhibition.

Placeholder: inhibition builds over days, not instantly.

Genetic variability

Placeholder: CYP2C9 poor metabolizers are hit hardest.

Warfarin Clearance Slows, Blood Levels Rise

Placeholder: unmetabolized warfarin accumulates in circulation.

• Up to 85%: Clearance Reduction (at high inhibition)
• Extended: Effective Half-Life (drug lingers longer)
• 3–7 days: Onset of INR Rise (after starting cannabis)
• ~1–2 weeks: Peak Effect Window (steady-state interaction)

Backlog in the bloodstream

Placeholder: warfarin molecules queue faster than they clear.

INR begins to drift

Placeholder: rising warfarin levels push INR upward.

Placeholder: INR lags days behind the enzyme blockade.

No dose change yet

Placeholder: same warfarin dose now hits much harder.

Elevated INR & Rising Bleeding Risk

Placeholder: supratherapeutic INR raises bleeding complications.

• High risk: INR >4 (bruising, minor bleeds)
• Severe risk: INR >6 (GI, intracranial bleed danger)
• Recheck INR: Recommended Action (within days of cannabis start)
• Often needed: Dose Adjustment (reduce warfarin, monitor closely)

Bleeding risk escalates

Placeholder: bruising, gum bleeding, GI bleeds become likely.

Placeholder: severe cases risk intracranial hemorrhage.

Monitoring recommendations

Placeholder: check INR sooner after any cannabis change.

Managing the interaction

Placeholder: adjust warfarin dose, counsel patient, recheck often.

Bleeding risk by INR band